Human-specific mutations in VMAT1 confer functional changes and multi-directional evolution in the regulation of monoamine circuits.
Anxiety
Human evolution
Monoamine transporter
SLC18A1
VMAT1
Journal
BMC evolutionary biology
ISSN: 1471-2148
Titre abrégé: BMC Evol Biol
Pays: England
ID NLM: 100966975
Informations de publication
Date de publication:
02 12 2019
02 12 2019
Historique:
received:
19
06
2019
accepted:
15
11
2019
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
1
2
2020
Statut:
epublish
Résumé
Neurochemicals like serotonin and dopamine play crucial roles in human cognitive and emotional functions. Vesicular monoamine transporter 1 (VMAT1) transports monoamine neurotransmitters, and its variant (136Thr) is associated with various psychopathological symptoms and reduced monoamine uptake relative to 136Ile. We previously showed that two human-specific amino acid substitutions (Glu130Gly and Asn136Thr/Ile) of VMAT1 were subject to positive natural selection. However, the potential functional alterations caused by these substitutions (Glu130Gly and Asn136Thr) remain unclear. To assess functional changes in VMAT1 from an evolutionary perspective, we reconstructed ancestral residues and examined the role of these substitutions in monoamine uptake in vitro using fluorescent false neurotransmitters (FFN), which are newly developed substances used to quantitatively assay VMATs. Immunoblotting confirmed that all the transfected YFP-VMAT1 variants are properly expressed in HEK293T cells at comparable levels, and no significant difference was seen in the density and the size of vesicles among them. Our fluorescent assays revealed a significant difference in FFN206 uptake among VMAT1 variants: 130Glu/136Asn, 130Glu/136Thr, and 130Gly/136Ile showed significantly higher levels of FFN206 uptake than 130Gly/136Asn and 130Gly/136Thr, indicating that both 130Glu and 136Ile led to increased neurotransmitter uptake, for which 136Thr and 136Asn were comparable by contrast. These findings suggest that monoamine uptake by VMAT1 initially declined (from 130Glu/136Asn to 130Gly/136Thr) in human evolution, possibly resulting in higher susceptibility to the external environment of our ancestors.
Sections du résumé
BACKGROUND
Neurochemicals like serotonin and dopamine play crucial roles in human cognitive and emotional functions. Vesicular monoamine transporter 1 (VMAT1) transports monoamine neurotransmitters, and its variant (136Thr) is associated with various psychopathological symptoms and reduced monoamine uptake relative to 136Ile. We previously showed that two human-specific amino acid substitutions (Glu130Gly and Asn136Thr/Ile) of VMAT1 were subject to positive natural selection. However, the potential functional alterations caused by these substitutions (Glu130Gly and Asn136Thr) remain unclear. To assess functional changes in VMAT1 from an evolutionary perspective, we reconstructed ancestral residues and examined the role of these substitutions in monoamine uptake in vitro using fluorescent false neurotransmitters (FFN), which are newly developed substances used to quantitatively assay VMATs.
RESULTS
Immunoblotting confirmed that all the transfected YFP-VMAT1 variants are properly expressed in HEK293T cells at comparable levels, and no significant difference was seen in the density and the size of vesicles among them. Our fluorescent assays revealed a significant difference in FFN206 uptake among VMAT1 variants: 130Glu/136Asn, 130Glu/136Thr, and 130Gly/136Ile showed significantly higher levels of FFN206 uptake than 130Gly/136Asn and 130Gly/136Thr, indicating that both 130Glu and 136Ile led to increased neurotransmitter uptake, for which 136Thr and 136Asn were comparable by contrast.
CONCLUSIONS
These findings suggest that monoamine uptake by VMAT1 initially declined (from 130Glu/136Asn to 130Gly/136Thr) in human evolution, possibly resulting in higher susceptibility to the external environment of our ancestors.
Identifiants
pubmed: 31791232
doi: 10.1186/s12862-019-1543-8
pii: 10.1186/s12862-019-1543-8
pmc: PMC6889191
doi:
Substances chimiques
Biogenic Monoamines
0
SLC18A1 protein, human
0
Vesicular Monoamine Transport Proteins
0
Serotonin
333DO1RDJY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Références
Am J Psychiatry. 1996 Apr;153(4):466-76
pubmed: 8599393
J Comp Neurol. 2017 Feb 1;525(2):319-332
pubmed: 27328754
Alcohol Clin Exp Res. 2016 Mar;40(3):474-81
pubmed: 26876819
Soc Cogn Affect Neurosci. 2016 Mar;11(3):413-22
pubmed: 26475872
Hum Genet. 1998 Sep;103(3):273-9
pubmed: 9799080
Neuroscience. 2013 Mar 1;232:32-44
pubmed: 23201251
Sci Rep. 2015 Feb 04;5:8242
pubmed: 25649757
Med Hypotheses. 2012 Feb;78(2):341-8
pubmed: 22153577
Science. 1996 Nov 29;274(5292):1527-31
pubmed: 8929413
Neuropsychopharmacology. 1999 Jun;20(6):517-24
pubmed: 10327421
Neurosci Lett. 2008 Mar 21;434(1):41-5
pubmed: 18249496
Proc Natl Acad Sci U S A. 2016 May 31;113(22):6178-81
pubmed: 27140612
Neuropsychopharmacology. 2006 Dec;31(12):2739-47
pubmed: 16936705
Clin Genet. 2003 Sep;64(3):190-7
pubmed: 12919132
Behav Genet. 2006 Mar;36(2):163-72
pubmed: 16402281
Gene. 2017 Aug 20;625:10-14
pubmed: 28476685
Neuro Endocrinol Lett. 2012;33(5):546-51
pubmed: 23090274
Neuropsychologia. 2011 Sep;49(11):2971-84
pubmed: 21803062
J Exp Biol. 2006 Dec;209(Pt 24):4858-68
pubmed: 17142674
FASEB J. 2000 Dec;14(15):2423-34
pubmed: 11099460
Proc Natl Acad Sci U S A. 1996 May 14;93(10):5166-71
pubmed: 8643547
J Biol Chem. 2006 Nov 3;281(44):33373-85
pubmed: 16926160
Evol Lett. 2018 Aug 21;2(5):499-510
pubmed: 30283697
Mol Psychiatry. 2000 Jul;5(4):357-62
pubmed: 10889545
Neuropsychobiology. 2008;57(1-2):55-60
pubmed: 18451639
Mol Biol Evol. 2007 Aug;24(8):1586-91
pubmed: 17483113
Horm Behav. 2015 Jan;67:60-5
pubmed: 25476609
J Neural Transm Gen Sect. 1993;93(1):75-82
pubmed: 8373557
Am J Phys Anthropol. 2018 Jan;165 Suppl 65:23-36
pubmed: 29380886
Curr Biol. 2018 Oct 8;28(19):3136-3142.e4
pubmed: 30245101
Brain Res. 2019 Jun 1;1712:151-157
pubmed: 30685272
Prog Brain Res. 2008;172:543-65
pubmed: 18772050
Brain Res Dev Brain Res. 1998 Sep 10;110(1):135-58
pubmed: 9733951
Mol Psychiatry. 2014 Jan;19(1):129-39
pubmed: 23337945
Nat Genet. 1996 Jan;12(1):78-80
pubmed: 8528256
Science. 2009 Jun 12;324(5933):1441-4
pubmed: 19423778
Cereb Cortex. 2008 Mar;18(3):584-97
pubmed: 17586605
Brain Res Brain Res Rev. 2003 Mar;41(2-3):268-87
pubmed: 12663083
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1108-E1116
pubmed: 29358369
Genomics. 1993 Dec;18(3):720-3
pubmed: 7905859
Int J Neuropsychopharmacol. 2016 Jul 05;19(7):
pubmed: 26861143
Proc Biol Sci. 2000 Jun 7;267(1448):1071-9
pubmed: 10885511
Neurosci Biobehav Rev. 2011 Mar;35(4):1042-51
pubmed: 20833199
Trends Cogn Sci. 2006 Apr;10(4):182-91
pubmed: 16530463
Neuropsychologia. 2009 Jun;47(7):1654-9
pubmed: 19397860
Front Neuroanat. 2011 Mar 29;5:21
pubmed: 21483723
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Gen Physiol. 2018 May 7;150(5):671-682
pubmed: 29666153
J Clin Psychiatry. 2000 Feb;61(2):77-8
pubmed: 10732653
J Cell Biol. 1994 Dec;127(5):1419-33
pubmed: 7962100
Science. 2017 Nov 24;358(6366):1027-1032
pubmed: 29170230
ACS Chem Biol. 2013 Sep 20;8(9):1947-54
pubmed: 23859623
J Mol Microbiol Biotechnol. 1999 Nov;1(2):257-79
pubmed: 10943556
J Comp Neurol. 2016 Jul 1;524(10):2117-29
pubmed: 26715195